PDC*mel / PDC line Pharma - LARVOL DELTA

Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses. (PubMed, Acta Pharm Sin B) - "Dendritic cell-based cancer vaccines (DC vaccines) have been proved efficient and safe in immunotherapy of various cancers, including melanoma, ovarian and prostate cancer...Given the above, it demonstrated that DC-SNU loaded with SecPen and ubiquitin-fused NY-ESO-1 could elicit stronger and specific T cell immune responses. This strategy can be used as a platform for DC vaccine preparation and applied to various cancers treatment."

Journal • Genito-urinary Cancer • Immune Modulation • Inflammation • Melanoma • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Targeted Protein Degradation • CD40 • CTAG1B • IFNG • TNFA

Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine. (PubMed, Ther Adv Med Oncol) - "MTX can function as a potent adjuvant in DC vaccines by increasing antigen presentation and T cell priming. Our findings provide a new strategy for the application of DC-based anti-tumour immunotherapy."

Journal • Oncology • IFNG

Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. (PubMed, J Control Release) - "In parallel, the vaccination induced significant prophylactic anti-tumor effects against a model tumor that stably expressed the OVA protein. Based on the above findings, the ssPalmE-KALA appears to be a potent ex vivo DCs-based RNA vaccine platform."

Journal • Preclinical • Infectious Disease • Oncology

AN ANTICANCER DRUG COCKTAIL OF Three Kinase Inhibitors Improved Response to a DENDRITIC CELL-BASED CANCER VACCINE. (PubMed, Cancer Immunol Res) - "We identified AKT inhibitor MK2206, DNA-PK inhibitor NU7441, and MEK inhibitor trametinib as the compounds most effective at modulating moDC immunogenicity...MKNUTRA treatment imparted to ICT107, a glioblastoma (GBM) DC-based vaccine that has completed phase II trials, an increased ability to stimulate patient-derived autologous CD8 T cells against the brain tumor antigens IL13Rα2 and TRP2In vivo, treating ICT107 with MKNUTRA, prior to injection into mice with an established GBM tumor, reduced tumor growth kinetics. This response was associated with an increased frequency of tumor-reactive lymphocytes within tumors and in peripheral tissues. These studies broaden the application of targeted anticancer drugs and highlight their ability to increase moDC immunogenicity."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. (PubMed, J Immunother Cancer) - "Ascites monocytes are naturally loaded with tumor antigen and can perform as potent APCs following short ex vivo activation. This novel ascites APC vaccine can be rapidly prepared in 48 hours with a straightforward and affordable manufacturing process, and would be an attractive therapeutic vaccine for OC."

IO Biomarker • Journal • Immune Modulation • Inflammation • Oncology • Ovarian Cancer • Solid Tumor

Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance. (PubMed, Autophagy) - "For potential clinical application, DC vaccine preparations treated with tumor cells that were already pretreated with chloroquine and shikonin further enhanced the antimetastatic activity of 4T1 tumors and reduced the effective dosage of doxorubicin. The enhanced immunogenicity and vaccine efficacy obtained via shikonin and chloroquine cotreatment of tumor cells may thus constitute a compelling strategy for developing cancer vaccines via the use of a combinational drug treatment."

Journal